News
CNSY
1.250
-26.90%
-0.460
Weekly Report: what happened at CNSY last week (1026-1030)?
Weekly Report · 2d ago
Cerenome Completes Enrollment In Phase 2 ReSPECT-GBM Trial Of REYOBIQ In Recurrent Glioblastoma; Topline Data Expected Mid-2027
Benzinga · 5d ago
Cerenome To Report Poster Presentation Of Interim Data From Its Current ReSPECT-LMM Multidose Trial Of REYOBIQ At 31st Annual Meeting And Education Day
Benzinga · 10/27 11:33
Weekly Report: what happened at CNSY last week (1019-1023)?
Weekly Report · 10/26 09:01
Cerenome announces new dual mechanism of action for REYOBIQ
TipRanks · 10/21 13:11
Cerenome Presents New Preclinical Data At 16th Biennial Rivkin Ovarian Cancer Research Symposium Regarding Immunomodulatory Properties Of REYOBIQ
Benzinga · 10/21 11:31
Weekly Report: what happened at CNSY last week (1012-1016)?
Weekly Report · 10/19 09:01
New Strong Sell Stocks for October 15th
NASDAQ · 10/15 07:47
Weekly Report: what happened at CNSY last week (1005-1009)?
Weekly Report · 10/12 09:01
Cerenome Launches CNSide® CSF Molecular Profile Tests
Barchart · 10/06 06:30
Weekly Report: what happened at CNSY last week (0928-1002)?
Weekly Report · 10/05 09:01
Cerenome Updates Investor Presentation on CNS Oncology Strategy
TipRanks · 10/02 11:58
Cerenome Is Maintained at Buy by Lake Street
Dow Jones · 10/01 16:16
Cerenome Price Target Cut to $31.00/Share From $50.00 by Lake Street
Dow Jones · 10/01 16:16
Lake Street Maintains Buy on Cerenome, Lowers Price Target to $31
Benzinga · 10/01 16:06
Cerenome price target lowered to $31 from $50 at Lake Street
TipRanks · 10/01 12:40
Cerenome Anticipates $1.55M In Payer Billings In Q3
Benzinga · 09/30 11:33
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Barchart · 09/30 06:30
Weekly Report: what happened at CNSY last week (0921-0925)?
Weekly Report · 09/28 09:01
5 Biotech Stocks Making Headlines - ADRX, CNSY, JAGX, AGL, ONCO
NASDAQ · 09/25 18:41
More
Webull provides a variety of real-time CNSY stock news. You can receive the latest news about Cerenome, Inc through multiple platforms. This information may help you make smarter investment decisions.
About CNSY
Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.